Several LIMK inhibitors have been developed for the treatment of conditions such as breast cancer (BMS3, LX7101, Pyr1) (Harrison et al., 2015; Prunier et al., 2016; Malvi et al., 2020), pancreatic cancer (T56-LIMKi) (Rak et al., 2014), Alzheimer’s disease (SR7826) (Henderson et al., 2019), Leukemia (Pyr1) (Prudent et al., 2012), Glaucoma and ocular hypertension (LX7101) (Harrison et al., 2009; Harrison et al., 2015). This evidence concerns the gene LIMK1 and breast carcinoma.